证券之星消息，截至2025年11月27日收盘，联影医疗(688271)报收于132.1元，上涨0.15%，换手率 0.42%，成交量3.49万手，成交额4.6亿元。 联影医疗2025年三季报显示，前三季度公司主营收入88.59亿元，同比上升27.39%；归母净利润11.2亿 元，同比上升66.91%；扣非净利润10.53亿元，同比上升126.94%；其中2025年第三季度，公司单季度主 营收入28.43亿元，同比上升75.41%；单季度归母净利润1.22亿元，同比上升143.8%；单季度扣非净利 润8761.41万元，同比上升126.24%；负债率30.08%，投资收益6068.47万元，财务费用-4382.33万元，毛 利率47.02%。联影医疗（688271）主营业务：提供高性能医学影像设备、放射治疗产品、生命科学仪 器及医疗数字化、智能化解决方案。 11月27日的资金流向数据方面，主力资金净流出342.16万元，占总成交额0.74%，游资资金净流出 2949.9万元，占总成交额6.42%，散户资金净流入3292.06万元，占总成交额7.16%。 近5日资金流向一览见下表： | 日期 收盘价 涨跌幅 主力 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a positive performance with a closing price of 133.5 yuan, reflecting a 2.15% increase on November 21, 2025, despite mixed capital flows [1][2]. Capital Flow Summary - On November 21, 2025, the net outflow of main funds was 449.24 thousand yuan, accounting for 0.55% of the total transaction amount, while retail investors experienced a net outflow of 1005.25 thousand yuan, representing 1.23% of the total [1][2]. - In contrast, speculative funds saw a net inflow of 1454.49 thousand yuan, which is 1.78% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from main funds on multiple days, particularly on November 17, where the outflow reached 111 million yuan [2]. Financing and Margin Trading Data - On November 21, 2025, the financing buy amounted to 40.60 million yuan, while the financing repayment was 95.05 million yuan, resulting in a net repayment of 54.45 million yuan [2][3]. - The margin trading balance stood at 1.14 billion yuan, with a total of 65,200 shares in margin trading remaining [2][3]. Company Performance Metrics - United Imaging Healthcare reported a total market capitalization of 1100.25 billion yuan, ranking second in the medical device industry [5]. - The company’s net profit for the first three quarters of 2025 was 1.12 billion yuan, reflecting a year-on-year increase of 66.91%, with a significant rise in revenue of 27.39% to 8.86 billion yuan [5]. - The gross margin was reported at 47.02%, while the net margin was 12.44%, indicating strong profitability compared to industry averages [5]. Institutional Ratings and Target Price - In the last 90 days, 27 institutions have rated the stock, with 20 buy ratings and 7 hold ratings, indicating a generally positive outlook [6]. - The average target price set by institutions over the past 90 days is 175.6 yuan, suggesting potential upside from the current trading price [6].

资料显示，上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号，成立日期2011年3月21 日，上市日期2022年8月22日，公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为：销售医学影像诊断设备及放射治疗设备 81.29%，提供维修收入13.56%，其他(补充)4.68%，软件收入0.47%。 联影医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：精准医疗、人工智能、 医疗器械、大盘、百元股等。 截至9月30日，联影医疗股东户数3.24万，较上期增加96.28%；人均流通股25444股，较上期减少 29.23%。2025年1月-9月，联影医疗实现营业收入88.59亿元，同比增长27.39%；归母净利润11.20亿元， 同比增长66.91%。 11月21日，联影医疗盘中上涨2.00%，截至10:04，报133.31元/股，成交2.22亿元，换手率0.20%，总市 值1098.69亿元。 资金流向方面，主力资金净流入2428.28万元，特大单买入2848.98万元，占比12.81%，卖出1774.65万 元，占比7.9 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has experienced a decline, with a closing price of 131.11 yuan on November 19, 2025, down by 2.34% [1] Group 1: Stock Performance - On November 19, 2025, the stock had a turnover rate of 0.4%, with a trading volume of 32,800 hands and a transaction amount of 435 million yuan [1] - The net outflow of main funds was 14.797 million yuan, accounting for 3.4% of the total transaction amount, while retail investors saw a net outflow of 36.92 thousand yuan, representing 0.08% of the total [1][2] Group 2: Financial Metrics - As of the third quarter of 2025, United Imaging Healthcare reported a main business revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% [3] - The company’s gross profit margin stands at 47.02%, while the net profit margin is 12.44% [3] Group 3: Industry Comparison - United Imaging Healthcare's total market capitalization is 108.055 billion yuan, significantly higher than the industry average of 11.279 billion yuan, ranking 2nd in the industry [3] - The company has a price-to-earnings ratio of 72.34, which is higher than the industry average of 56.7, ranking 64th in the industry [3] Group 4: Analyst Ratings - In the past 90 days, 27 institutions have rated the stock, with 20 buy ratings and 7 hold ratings, and the average target price set by institutions is 175.45 yuan [4]

分红方面，联影医疗A股上市后累计派现6.41亿元。 机构持仓方面，截止2025年9月30日，联影医疗十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股1903.56万股，相比上期减少298.09万股。易方达上证科创板50ETF（588080）位居第八大 流通股东，持股1787.43万股，相比上期减少259.56万股。华夏上证科创板50成份ETF（588000）位居第 九大流通股东，持股1745.84万股，相比上期减少908.62万股。华宝中证医疗ETF（512170）退出十大流 通股东之列。 资料显示，上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号，成立日期2011年3月21 日，上市日期2022年8月22日，公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为：销售医学影像诊断设备及放射治疗设备 81.29%，提供维修收入13.56%，其他(补充)4.68%，软件收入0.47%。 联影医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：精准医疗、人工智能、 医疗器械、大盘、百元股等。 截至9月30日，联 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight increase, with a closing price of 134.25 yuan on November 18, 2025, reflecting a 0.19% rise, amidst mixed capital flows [1][2]. Financial Performance - For the first three quarters of 2025, United Imaging Healthcare reported a main business revenue of 8.859 billion yuan, a year-on-year increase of 27.39% [3]. - The net profit attributable to shareholders for the same period was 1.12 billion yuan, up 66.91% year-on-year [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 2.843 billion yuan, representing a 75.41% increase year-on-year [3]. - The net profit for the third quarter was 122 million yuan, a significant rise of 143.8% year-on-year [3]. - The company’s gross profit margin stands at 47.02%, while the net profit margin is 12.44% [3]. Market Position - United Imaging Healthcare has a total market capitalization of 110.643 billion yuan, ranking 2nd in the medical device industry [3]. - The company’s net assets amount to 20.805 billion yuan, placing it 3rd in the industry [3]. - The price-to-earnings ratio (P/E) is 74.08, which is higher than the industry average of 55.31, ranking 64th [3]. - The price-to-book ratio (P/B) is 5.32, compared to the industry average of 4.04, ranking 104th [3]. Capital Flow Analysis - On November 18, 2025, the net outflow of main capital was 35.0896 million yuan, accounting for 6.46% of the total transaction amount [1][2]. - Retail investors saw a net inflow of 15.9243 million yuan, representing 2.93% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced significant fluctuations in capital flow, with notable net outflows on several days [2]. Analyst Ratings - In the last 90 days, 27 institutions have provided ratings for United Imaging Healthcare, with 20 buy ratings and 7 hold ratings [4]. - The average target price set by institutions over the past 90 days is 175.45 yuan [4].

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 6.28%, indicating volatility in market performance [1]. Financial Performance - For the period from January to September 2025, United Imaging Healthcare reported a revenue of 8.859 billion yuan, representing a year-on-year growth of 27.39% [2]. - The net profit attributable to shareholders for the same period was 1.120 billion yuan, showing a significant increase of 66.91% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for United Imaging Healthcare reached 32,400, an increase of 96.28% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 29.23% to 25,444 shares [2]. - The stock's trading activity showed a net outflow of 58.49 million yuan from main funds, with significant selling pressure observed [1]. Company Overview - United Imaging Healthcare, established on March 21, 2011, and listed on August 22, 2022, specializes in high-performance medical imaging equipment, radiation therapy products, and medical digital solutions [1]. - The company's revenue composition includes 81.29% from medical imaging diagnostic equipment and radiation therapy equipment sales, 13.56% from maintenance services, and 4.68% from other sources [1]. Institutional Holdings - As of September 30, 2025, major institutional shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable reductions in their holdings [3].

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a slight decline, with a closing price of 141.5 yuan on November 11, 2025, reflecting a decrease of 0.19% [1] Financial Performance - For the first three quarters of 2025, the company's main revenue reached 8.859 billion yuan, an increase of 27.39% year-on-year - The net profit attributable to shareholders was 1.12 billion yuan, up 66.91% year-on-year - The non-recurring net profit was 1.053 billion yuan, a significant increase of 126.94% year-on-year - In Q3 2025, the company reported a single-quarter main revenue of 2.843 billion yuan, a year-on-year increase of 75.41% - The single-quarter net profit attributable to shareholders was 122 million yuan, up 143.8% year-on-year - The single-quarter non-recurring net profit was 87.614 million yuan, an increase of 126.24% year-on-year - The company's debt ratio stands at 30.08%, with investment income of 606.847 million yuan and financial expenses of -438.233 million yuan [3] Market Position and Valuation - United Imaging Healthcare's total market value is 116.618 billion yuan, ranking 2nd in the medical device industry - The company's net assets are 20.805 billion yuan, ranking 3rd in the industry - The net profit of 1.12 billion yuan places the company 5th in the industry - The price-to-earnings ratio (P/E) is 78.08, which is higher than the industry average of 62.82, ranking 65th - The price-to-book ratio (P/B) is 5.6, compared to the industry average of 4.02, ranking 106th - The gross margin is 47.02%, lower than the industry average of 51.22%, ranking 77th - The net margin is 12.44%, higher than the industry average of 9.57%, ranking 56th - The return on equity (ROE) is 5.5%, significantly higher than the industry average of 0.15%, ranking 46th [3] Institutional Ratings - In the last 90 days, 27 institutions have rated the stock, with 20 buy ratings and 7 hold ratings - The average target price set by institutions over the past 90 days is 174.43 yuan [4]

Core Insights - The stock price of United Imaging Healthcare increased by 2.00% on November 5, reaching 139.74 CNY per share, with a total market capitalization of 115.168 billion CNY [1] - The company reported a year-to-date stock price increase of 10.74%, but a decline of 4.65% over the last five trading days [1][2] - For the period from January to September 2025, United Imaging Healthcare achieved a revenue of 8.859 billion CNY, representing a year-on-year growth of 27.39%, and a net profit of 1.120 billion CNY, up 66.91% year-on-year [2] Financial Performance - The company’s main business revenue composition includes 81.29% from sales of medical imaging diagnostic equipment and radiation therapy equipment, 13.56% from maintenance services, 4.68% from other sources, and 0.47% from software [1] - Cumulative cash dividends since the company's A-share listing amount to 641 million CNY [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 32,400, a rise of 96.28%, while the average number of circulating shares per person decreased by 29.23% to 25,444 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which holds 19.036 million shares, and several ETFs, with notable reductions in holdings compared to the previous period [3]

Core Viewpoint - The stock of United Imaging Healthcare (688271) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Financial Performance - As of November 4, 2025, United Imaging Healthcare's stock closed at 137.0 yuan, down 0.5% with a trading volume of 38,300 hands and a transaction value of 525 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 2.843 billion yuan, a year-on-year increase of 75.41%, and a net profit attributable to shareholders of 122 million yuan, up 143.8% year-on-year [3]. - For the first three quarters of 2025, the company achieved a main revenue of 8.859 billion yuan, a 27.39% increase year-on-year, and a net profit of 1.12 billion yuan, reflecting a 66.91% increase year-on-year [3]. Capital Flow Analysis - On November 4, 2025, the net outflow of main funds was 19.68 million yuan, accounting for 3.75% of the total transaction value, while retail investors experienced a net outflow of 6.56 million yuan, representing 1.25% of the total transaction value [1][2]. - Over the past five days, the stock has seen significant fluctuations in capital flow, with the largest net outflow of main funds recorded on November 3, amounting to 154 million yuan [2]. Industry Comparison - United Imaging Healthcare's total market capitalization stands at 112.91 billion yuan, ranking second in the medical device industry, while its net profit of 1.12 billion yuan places it fifth in the same sector [3]. - The company's price-to-earnings ratio (P/E) is 75.59, which is higher than the industry average of 60.95, indicating a premium valuation compared to peers [3]. Analyst Ratings - In the last 90 days, 26 institutions have rated the stock, with 20 buy ratings and 6 hold ratings, suggesting a generally positive outlook among analysts [4].